Literature DB >> 17607149

Long-term disability of class A patients with Ménière's disease after treatment with intratympanic gentamicin.

Maria Soledad Boleas-Aguirre1, Noelia Sánchez-Ferrandiz, Francisco Guillén-Grima, Nicolas Perez.   

Abstract

OBJECTIVE: The main objective of this study was to characterize the residual vestibular symptoms and disability in patients with Ménière's disease who had achieved complete control of vertigo through intratympanic gentamicin treatment. Furthermore, we assessed whether the Functional Level Score prior to treatment reflected the posttreatment symptoms and disability. STUDY
DESIGN: Prospective.
SETTING: Tertiary medical center. PATIENTS: This study involved 103 patients with Ménière's disease treated with intratympanic gentamicin who, after a long-term follow up, have not suffered new vertigo spells and were not subject to any major modification in their treatment.
METHODS: At inclusion and at the last follow-up visit after a minimum of 3 years of ending the treatment, the clinical status (number of vertigo spells), the unsteadiness as well as the disability produced by the disease, symptoms of anxiety, and compensation were asked using specific questionnaires. The results before and after treatment were analyzed using nonparametric tests.
RESULTS: After a 5-year follow-up, complete control of vertigo was obtained in 81% of the patients with Ménière's disease who were treated with intratympanic gentamicin. Of them, 15.5% still complained of unsteadiness. A functional level of 6 or unsteadiness after treatment are related with a nonreduction in disability after long-term control of vertigo spells.
CONCLUSIONS: The efficacy of gentamicin administered intratympanically is high after long-term follow-up as shown by the disappearance of vertigo spells and by the reduction in disability, increase in perception of quality of life, and reduction in anxiety related to vestibular symptoms. Unsteadiness, although an infrequent complaint, determines a level of almost similar severity in those issues. Special care must be taken with patients with a Functional Level Scale score of 6 at the time of beginning treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17607149     DOI: 10.1097/MLG.0b013e318065aa27

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  Therapeutic illusion: another frontier in Ménière's disease.

Authors:  Nicolas Pérez-Fernández; Eduardo Martín-Sanz
Journal:  Ann Transl Med       Date:  2016-10

2.  Successful treatment of relapsed Ménière's disease using selective serotonin reuptake inhibitors: A report of three cases.

Authors:  Fumiyuki Goto; Tomoko Tsutsumi; Kaoru Ogawa
Journal:  Exp Ther Med       Date:  2013-11-15       Impact factor: 2.447

3.  Low-Dose Intratympanic Gentamicin for Unilateral Ménière's Disease: Accuracy of Early Vestibulo-Ocular Reflex Gain Reduction in Predicting Long-Term Clinical Outcome.

Authors:  Ricardo Wegmann-Vicuña; Raquel Manrique-Huarte; Diego Calavia-Gil; Eduardo Martín-Sanz; Pedro Marques; Nicolas Perez-Fernandez
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.